PlainRecalls
FDA Drug Low Class III Terminated

Tivicay (dolutegravir) Tablets 50 mg, 30-count Bottle, Rx Only, Manufactured for: ViiV Healthcare RTP, NC 27709, NDC 49702-228-13.

Reported: June 1, 2022 Initiated: May 13, 2022 #D-0896-2022

Product Description

Tivicay (dolutegravir) Tablets 50 mg, 30-count Bottle, Rx Only, Manufactured for: ViiV Healthcare RTP, NC 27709, NDC 49702-228-13.

Reason for Recall

Labeling: incorrect or missing lot and/or expiration date. An incorrect expiration date was printed on the product labeling with an expiration date of January 2027, whereas the correct expiration date is September 2026.

Details

Recalling Firm
GlaxoSmithKline LLC
Units Affected
328 bottles
Distribution
Nationwide in the U.S.
Location
Zebulon, NC

Frequently Asked Questions

What product was recalled?
Tivicay (dolutegravir) Tablets 50 mg, 30-count Bottle, Rx Only, Manufactured for: ViiV Healthcare RTP, NC 27709, NDC 49702-228-13.. Recalled by GlaxoSmithKline LLC. Units affected: 328 bottles.
Why was this product recalled?
Labeling: incorrect or missing lot and/or expiration date. An incorrect expiration date was printed on the product labeling with an expiration date of January 2027, whereas the correct expiration date is September 2026.
Which agency issued this recall?
This recall was issued by the FDA Drug on June 1, 2022. Severity: Low. Recall number: D-0896-2022.